慢性非特异性溃疡性结肠炎26例临床分析

目的探讨慢性非特异性溃疡性结肠炎的临床特点和治疗效果。方法选择我院2008年7月至2012年2月慢性非特异性溃疡性结肠炎患者26例,分析其临床症状和内镜下表现。本组患者根据患者病变严重程度、活动度和病变范围实施临床治疗。轻中度患者给予5-氨基水杨酸类药物美沙拉嗪治疗;重度患者给予波尼松,或者静脉滴注氢化可的松;合并有肠道感染的可给予喹诺酮类、替硝唑等抗感染治疗。结果本组患者经治疗后临床症状和体征均有不同程度缓解,其中1例患者服用柳氮磺胺吡啶后出现皮疹,换药后皮疹好转至消失;1例患者在治疗过程中合并消化道出血而转至外科手术治疗。本组患者中痊愈19例,有效6例,无效1例。总有效效率为96.1%。结论慢性非特异性溃疡性结肠炎主要是消化系统临床表现,内镜和病理组织学检查有助于其临床诊断,以5-氨基水杨酸类制剂同时辅以糖皮质激素类药物为主,根据患者具体情况给予个体化及综合性治疗有助于改善患者预后。     

甲硝唑的新用途

治疗慢性溃疡性结肠炎对47例经纤维结肠镜确诊的慢性非特异性溃疡性结肠炎患者用甲硝唑及安慰剂对照治疗,治疗组37例,对照组10例,结果     

健脾止泻汤治疗慢性非特异性溃疡性结肠炎的临床观察

目的：观察健脾止泻汤治疗慢性非特异性溃疡性结肠炎的临床效果。方法选取住院及门诊收治的慢性非特异性溃疡性结肠炎患者60例,随机分为治疗组和对照组各30例,治疗组予自拟健脾止泻汤治疗,对照组予柳氮磺吡啶治疗,治疗3个疗程后观察2组临床疗效。结果治疗组总有效率为90.0%明显高于对照组的76.7%,差异有统计学意义（P ＜0.05）。结论健脾止泻汤用于治疗慢性非特异性溃疡性结肠炎效果良好,值得临床推广应用。     

蒙中药合用治疗溃疡性结肠炎的体会

近年来国内溃疡性结肠炎(UC)发病率逐年上升趋势(1),临床上20-40岁年龄多见,探索有效的治疗方法逐渐提上日程。溃疡性结肠炎是一种慢性非特异性的结肠炎,具有反复发作的特点。笔者采用蒙中药结合治疗本病22例,取得较好的疗效。现汇报如下:1、临床资料1.1诊断依据依据1993年全国慢性非感染性肠道疾病太原会议溃疡性结肠炎的诊断标准(2)。     

慢性非特异性溃疡性结肠炎30例疗效观察

慢性非特异性溃疡性结肠炎,是一种病因未明的慢性结肠炎症,病变以溃疡为主,限于大肠黏膜与黏膜下层.我们从2004年10月-2006年10月,治疗30例慢性非特异性溃疡性结肠炎患者,获得较好疗效,现报告如下:     

加味燮理散治疗特异性溃疡性结肠炎38例

近 5年来,运用加味燮理散治疗溃疡性结肠炎(UC)) 38例,现总结如下: 1 临床资料 1.1 诊断标准:参照 1992年全国慢性非特异性溃疡性结肠炎临汾会议诊断标准.     

红花注射液辅助治疗溃疡性结肠炎的临床观察

溃疡性结肠炎是一种原因不明的肠道慢性非特异性炎性疾病,好发于直肠和乙状结肠,近年来发病率有上升趋势。3年来我科应用红花注射液辅助治疗溃疡性结肠炎取得满意效果,现报道如下。1材料与方法1.1一般资料选择2008年3月至2010年4月住院溃疡性结肠炎患者64例,诊断均符合2000年成都全国炎症性肠病会议修订的溃疡性结肠炎诊断标准[1]。     

40例药物保留灌肠治疗溃疡性结肠炎的护理体会

溃疡性结肠炎是一种目前尚未查明病因的慢性非特异性炎症性疾病,也称非特异性溃疡性结肠炎,病变主要限于大肠黏膜与黏膜下层,以腹泻、腹痛、黏液脓血便为主要临床表现。病程迁延不愈,难以根治。治疗中药物保留灌肠是其行之有效的方法之一。2009年1月至2010年6月,我科采用     

中西药结合保留灌肠治疗溃疡性结肠炎疗效观察

溃疡性结肠炎（Ulcerative Colitis,UC）又称慢性非特异性结肠炎或特发性溃疡性结肠炎,病程长,易复发,治疗困难。2004年9月至2008年2月邓州市第三人民医院对47例溃疡性结肠炎住院患者使用中西药结合保留灌肠治疗,疗效较好,报告如下。     

中药灌肠治疗慢性非溃疡性结肠炎46例

目的探讨中药方煎熬中药液后保留灌肠治疗慢性非溃疡性结肠炎的疗效。方法对46例辨证为湿热型的慢性非溃疡性结肠炎患者均用自拟中药方进行保留灌肠治疗2个疗程,并对其疗效进行评估。结果 46例患者治愈37例,有效6例,无效3例,总有效率为93.47%。结论中药灌肠治疗慢性非溃疡性结肠炎具有抗炎、消肿、止血及双向调节作用。     

坏疽性脓皮病伴溃疡性结肠炎继发肛瘘一例

坏疽性脓皮病伴溃疡性结肠炎继发肛瘘者少见,相关治疗方案亦少见报道,本文报告1例为坏疽性脓皮病 伴溃疡性结肠炎继发肛瘘,持续应用激素联合免疫抑制剂效果不佳,改用生物制剂后好转的诊治经过。     

Review article: insurance risks for patients with ulcerative colitis or Crohn's disease

Prospective population-based studies have allowed a re-evaluation of the risks of insuring patients with ulcerative colitis or Crohn's disease. Life expectancy, the risk of cancer and working capacity are very much better than previously recognised and are normal for many patients. Three population-based studies in ulcerative colitis have shown a mortality similar to or slightly less than the general population except in the first year after diagnosis, whilst two have shown a slightly higher mortality (standardized mortality ratio, SMR=1.4), except for those with proctitis. In Crohn's disease, two population-based studies have also shown an increased mortality (SMR=1.4), which is similar to that of unskilled manual labourers (SMR=1.43) from all causes of death. Three other studies have shown no increase in overall mortality, except in the first 5 years after diagnosis, in those with proximal small intestinal disease and in some patients needing multiple operations. Insurance risks should be evaluated on an individual basis, after details of the extent and pattern of disease have been obtained. Although the 'standard life' in insurance terms differs from that of the general population, because people who seek life assurance are self-selected from a more affluent section of society, many patients can be identified who have a particularly good prognosis. These include patients with ulcerative proctitis, those with left-sided colitis in extended remission (>12 months), and patients more than 30 years old with localized ileal or ileocaecal Crohn's disease that has responded to treatment. From the published data, it is difficult to justify increasing the insurance premium in such patients.     

溃疡性结肠炎的治疗现状及前景

溃疡性结肠炎是结、直肠慢性非特异性炎症性疾病,多呈反复发作的慢性病程。本病治疗难度大,与结肠癌的发病有关,被WHO列为现代难治病之一。目前溃疡性结肠炎的治疗手段多样,出现了许多新技术如生物靶向治疗、干细胞移植等,现将近年来溃疡性结肠炎现代医学研究进展进行综述。     

Campylobacter colitis.

Eleven consecutive patients with diarrhoea from whose stools campylobacter were isolated were investigated by sigmoidoscopy and rectal biopsy. Eight had definite proctitis, and in seven biopsy specimens were abnormal with histological changes ranging from non-specific colitis to gross colitis with goblet-cell depletion and crypt-abscess formation. Nine of the patients passed blood in their stools, and in all but one abdominal pain was a feature of the illness. Severe campylobacter colitis may be clinically, sigmoidoscopically, and histologically difficult to differentiate from ulcerative colitis and is a differential diagnosis in acute colitis.     

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006

BACKGROUND: Infliximab has been shown to be of benefit in the treatment of ulcerative colitis but long-term colectomy rates remain unknown. AIMS: To review the rate of colectomy after infliximab for ulcerative colitis and to identify factors that might predict the need for colectomy. METHODS: We conducted a retrospective cohort study of patients with active ulcerative colitis treated with infliximab between 2000 and 2006. The primary outcome was colectomy-free survival. Disease and treatment characteristics and complications were documented. RESULTS: Thirty patients were treated with infliximab for refractory ulcerative colitis. Sixteen (53%) came to colectomy a median of 140 days after their first infusion (range 4-607). There was no difference in colectomy between those receiving infliximab for acute severe ulcerative colitis failing intravenous steroids (8/14) and out-patients with steroid-refractory ulcerative colitis (8/16). Only 17% (5/30) achieved a steroid-free remission after a median follow-up of 13 months (range 2-72). Univariate analysis showed that a younger age at diagnosis of colitis was significantly associated with an increased rate of colectomy (27.5 years vs. 38.7 years, P = 0.016). CONCLUSION: Over half the patients studied came to colectomy. Of those avoiding colectomy, only five (17%) sustained a steroid-free remission.     

Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single-blind comparative study

Background : Sucralfate is a non-absorbable aluminium salt of sucrose octasulphate which in recent studies has proved to be of possible use in the treatment of active distal ulcerative colitis.
Aim : The aim of this randomized, single-blind, study was to compare 10 g sucralfate with 100 mg hydrocortisone enemas in the treatment of 40 patients (26 male and 14 female; mean age 36.5 years, range 18–65 years) with active ulcerative proctitis, twice daily for 4 weeks.
Methods : A clinical, sigmoidoscopic and histological assessment was performed before and 4 weeks after the start of the therapy.
Results : Both treatments showed significant within-treatment improvement in clinical, endoscopic and histological grades (Wilcoxon's matched pair test, P <0.05). Between-treatment comparisons, using the Mann–Whitney test, showed that hydrocortisone is more effective than sucralfate in improving the clinical score ( P <0.05).
Conclusions : Sucralfate enema treatment, which was significantly less effective than hydrocortisone enemas in this study, has very limited use in the treatment of active ulcerative proctitis.     

156例溃疡性结肠炎临床治疗研究

目的对溃疡性结肠炎科学诊断与治疗开展进行分析研究,以进一步提高诊治水平。方法选取本院2009年1月～2010年12月收治的156例溃疡性结肠炎患者临床诊治资料开展分析。结果采取药物口服以及药物灌肠相结合对症治疗,辅之以健康教育,102例患者治愈,54例患者明显好转,治疗有效率为100％。结论在溃疡性肠炎治疗中,采取121服药物加药物灌肠相结合的综合治疗方式,并对患者强化自我保健以及健康成活方式引导,能够提高综合治疗效果,并有效预防复发,有利于患者健康。     

PPH联合挂线治疗混合痔合并肛瘘的疗效观察

目的：观察分析吻合器痔环切术（PPH）联合挂线治疗混合痔合并肛瘘的疗效。方法对2012年6月～2013年6月间收治的71例采用PPH联合挂线治疗的混合痔合并肛瘘患者的临床资料进行回顾性分析,观察PPH联合挂线治疗混合痔合并肛瘘的疗效。结果经术后随访,治愈率为100%（71/71）,手术时间为（70.2±5.5）min,挂线脱落时间为（8.5±2.9）d,住院时间为11～17 d,平均（13.0±2.5）d,治疗后患者痔回缩满意,且肛瘘愈合完全。患者术后43例出现肛门功能不良,2例患者出现肛缘水肿,未有假性愈合、肛门狭窄、肛门失禁、吻合口狭窄等严重并发症发生。1例患者复发,复发率为1.41%（1/71）。结论PPH联合挂线治疗混合痔合并肛瘘的疗效显著,具有治愈率高、复发率低、并发症少的优点,值得临床推广应用。     

美沙拉秦治疗溃疡性结肠炎的多中心研究

目的：观察美沙拉秦对我国溃疡性结肠炎病人的疗效。方法：溃疡性结肠炎病人１００例，其中４１例单纯溃疡性直肠炎为栓剂组，其他５９例为片剂组。栓剂组（男性２４例，女性１７例，年龄４３±ｓ１１ａ）予美沙拉秦栓剂１．０ｇ纳肛，ｂｉｄ，疗程８ｗｋ；片剂组（男性２９例，女性３０例，年龄４４±１４ａ）予美沙拉秦缓释片０．５～１．０ｇ，ｐｏ，ｔｉｄ～ｑｉｄ，疗程８ｗｋ；疗程结束后复查肠镜并作活检。结果：２组病人治疗后肠镜及组织学所见均显著改善，栓剂组总有效率为９８％，片剂组为９５％，前者无不良反应，后者不良反应轻微。结论：美沙拉秦治疗我国溃疡性结肠炎疗效显著而又安全。     

星状神经节阻滞对慢性溃疡性结肠炎患者细胞因子(白细胞介素-8、TNF-α)的影响

目的观察星状神经节阻滞治疗对慢性溃疡性结肠炎患者的临床症状及细胞因子(白细胞介素-8、TNF-α)变化的影响进行分析。方法随机抽取2010年2月至2012年2月期间患慢性溃疡性结肠炎的患者60例,随机分为两组,即对照组和观察组,每组各有30例慢性溃疡性结肠炎患者。对照组中的患者进行口服柳氮磺吡啶片治疗,而观察组中的患者采取星状神经节阻滞治疗。对两组慢性溃疡性结肠炎患者的临床治疗效果进行比较分析。结果从腹痛、里急后重、脓血便以及便次这几个方面来说,观察组患者行星状神经节阻滞治疗前后的数据对比差异显著(P<0.05),数据具备统计学意义;以上指标自对照组与观察组相比,相关数据仍然存在显著差异(P<0.05),数据具备统计学意义;观察组治疗后细胞因子水平变化显著(P<0.05),具有统计学意义。结论在对慢性溃疡性结肠炎患者进行治疗时,采取星状神经阻滞术治疗,能够有效的提高患者的疾病治疗有效率,缓解患者的疼痛情况,有一定的积极影响。